Lymphatic Filariasis Elimination Program
The Latest News
Feb. 28, 2010
Winter Weekend Auction Raises $1,322,300 for Carter Center
Peace and Health Programs >
Other news >>
Feb. 28, 2010
Winter Weekend Auction Raises $1,322,300 for Carter Center
Peace and Health Programs >
Other news >>
Print
This Page
E-mail
This Page
|
"Lymphatic Filariasis is a forgotten disease of forgotten people. When this disease strikes the world's most vulnerable populations, it robs people of any semblance of a quality of life they once had." - Dr. Frank O. Richards Jr., Director, Lymphatic Filariasis Elimination Program |
The Carter Center Lymphatic Filariasis
Elimination Program Lymphatic filariasis, a parasitic disease transmitted by mosquitoes, is a leading cause of permanent and long-term disability. In its severest form, lymphatic filariasis leads to elephantiasis — a crippling condition in which limbs or other parts of the body are grotesquely swollen or enlarged. In communities endemic with lymphatic filariasis, as many as 10 percent of women can be affected with swollen limbs and 50 percent of men can suffer from mutilating genital disease. These conditions have a devastating effect on the quality of life of those affected, impacting them not only physically but also emotionally and economically. In a collaborative effort, The Carter Center and its partners are working to show that the transmission of lymphatic filariasis can be interrupted on a large scale in Nigeria with mass community drug treatment and health education. In 2007, 3.4 million mass treatments were distributed to prevent lymphatic filariasis in the two Nigerian states of Plateau and Nasarawa--a remarkable 93 percent of the eligible population.
The strategy for elimination is based on treating everyone eligible to take the medicine living in an affected community with a dose of two drugs: ivermectin (Mectizan®, donated by Merck & Co., Inc.) and albendazole (donated by GlaxoSmithKline) in sub-Saharan Africa or diethylcarbamazine and albendazole elsewhere.
Integrating Treatment The Carter Center's Lymphatic Filariasis Elimination Program is based on the same community education and drug distribution system as the Center's River Blindness Program. In fact, the drug Mectizan, which is used in combination with albendazole to prevent transmission of lymphatic filariasis, is the same drug used worldwide to prevent transmission of river blindness. After years of success distributing Mectizan for river blindness in Nigeria, the Center began a pilot project to determine the feasibility of adding albendazole to the treatment regimen in communities where both river blindness and lymphatic filariasis are endemic. Partnering for Support Elimination of lymphatic filariasis is only possible through collaboration with multiple organizations and agencies. Carter Center partners include the Nigeria Ministry of Health and the ministries of health in Plateau and Nasarawa states, as well as the Emory University Lymphatic Filariasis Support Center, the Centers for Disease Control and Prevention, the Bill & Melinda Gates Foundation, Merck, and GlaxoSmithKline. Most of all, through committed community action, Nigerians themselves are freeing their families and friends from the misery of lymphatic filariasis.
TOP |
|
RSS Feeds
Podcasts